Sign Out
Each ml of concentrate contains 20 mg of natalizumab.
When diluted (see Cautions for Usage), the solution for infusion contains approximately 2.6 mg/ml of natalizumab.
Natalizumab is a recombinant humanised anti-α4-integrin antibody produced in a murine cell line by recombinant DNA technology.
Excipient with known effect: Each vial contains 2.3 mmol (or 52 mg) sodium. When diluted in 100 ml sodium chloride 9 mg/ml (0.9%) the medicinal product contains 17.7 mmol (or 406 mg) sodium.
Excipients/Inactive Ingredients: Sodium phosphate (monobasic, monohydrate), Sodium phosphate (dibasic, heptahydrate), Sodium chloride, Polysorbate 80 (E433), Water for injections.
Continue with Google